Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079670 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of NVX-CoV2705
A Phase 3 study of COVID-19 and SARS CoV 2 Infection, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
- 10
- Study locations
NCT07079670: Active Phase 3 study of COVID-19 and SARS CoV 2 Infection, sponsored by Sanofi.
NCT07079670 is a Phase 3 study of COVID-19 and SARS CoV 2 Infection that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 676 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07079670, a Phase 3 study of COVID-19 and SARS CoV 2 Infection, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.
Primary Outcome
Pseudovirus neutralization (ID50) GMFR for the Omicron JN.1 subvariant at Day 28 following study vaccination.
Conditions Studied
Interventions
- BIOLOGICAL NVX-CoV2705
Study Locations (10)
Texas
- Investigational Site Number US047 - Austin
- Investigational Site Number US073 - Tomball
Arizona
- Investigational Site Number US404 - Phoenix
Illinois
- Investigational Site Number US395 - Melrose Park
Kansas
- Investigational Site Number US406 - Lenexa
Louisiana
- Investigational Site Number US294 - Lafayette
Michigan
- Investigational Site Number US407 - Southfield
Nebraska
- Investigational Site Number US326 - Omaha
Ohio
- Investigational Site Number US381 - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-06-16 |
| Phase | Phase 3 |
What the registry record for NCT07079670 still lists
NCT07079670 is an interventional study that assigns participants to a tested intervention. The registered 676 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which NVX-CoV2705 is the first listed.
NCT07079670 lists 10 locations in 9 states (Texas, Arizona, Illinois).
Frequently Asked Questions
What is clinical trial NCT07079670 about?
NCT07079670 is a clinical study titled "Safety and Immunogenicity of NVX-CoV2705". This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to ...
What is the current status of trial NCT07079670?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2025-10-09. Estimated completion is 2026-06-16.
What conditions does trial NCT07079670 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection.
What interventions are being tested in trial NCT07079670?
The interventions under investigation include: NVX-CoV2705 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07079670?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07079670 being conducted?
This trial has 10 study locations across Arizona, Illinois, Kansas, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07079670's enrollment target sits among peer trials
676 95th of 298 higher than 204 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07227337 · 676 participants · NA
Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI